source
- Replimune’s Tudriqev immunotherapy receives FDA accelerated approval for advanced melanomaReplimune announced that the FDA granted accelerated approval for its immunotherapy, now branded Tudriqev, in combination with Bristol Myers Squibb’s Opdivo. The decision follows two earlier reject…
- Takeda receives FDA approval for Orzeyful, first orexin agonist to treat all symptoms of narcolepsy type 1Takeda announced that the U.S. Food and Drug Administration has approved its drug oveporexton, which will be marketed under the name Orzeyful, for the treatment of narcolepsy type 1 in adults. The…